Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given an average rating of “Hold” by the seventeen research firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $490.8182.

MEDP has been the subject of a number of recent analyst reports. TD Cowen boosted their price objective on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Mizuho lifted their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Jefferies Financial Group upped their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. Truist Financial set a $555.00 price objective on shares of Medpace in a report on Monday, October 27th. Finally, Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th.

Medpace Price Performance

NASDAQ:MEDP opened at $561.65 on Friday. The company has a 50 day moving average price of $580.19 and a 200-day moving average price of $487.47. Medpace has a 1-year low of $250.05 and a 1-year high of $626.26. The firm has a market cap of $15.82 billion, a price-to-earnings ratio of 39.28, a price-to-earnings-growth ratio of 2.12 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter in the previous year, the company earned $3.01 earnings per share. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace will post 12.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, CFO Kevin M. Brady sold 3,000 shares of Medpace stock in a transaction on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. The trade was a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 668 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 387,925 shares of company stock worth $233,386,647. Corporate insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Several large investors have recently bought and sold shares of the business. Quent Capital LLC acquired a new position in shares of Medpace during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. purchased a new position in Medpace during the third quarter worth approximately $27,000. Quarry LP acquired a new position in Medpace during the third quarter worth $35,000. Root Financial Partners LLC purchased a new stake in Medpace in the 3rd quarter valued at $38,000. Finally, Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.